

+

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<div>Complete if Known</div> <div>Application Number To Be Accorded 09/675398</div> <div>Filing Date 09/29/00</div> <div>First Named Inventor Linas-Brunet, M. et al</div> <div>Group Art Unit 1626</div> <div>Examiner Name J. Oswecki</div> <div>Attorney Docket Number 13/068-3-D3</div>	
<div>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</div> <div>(use as many sheets as necessary)</div>					
Sheet	1	of	2		

[illegible][illegible]

Examiner Signature	<i>J. J. Amick</i>	Date Considered	4-12-01
-----------------------	--------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Application Number		To Be Accorded 09/675 398			
Filing Date		09/29/00			
First Named Inventor		Llinas-Brunet, M. et al			
Group Art Unit		1626			
Examiner Name		OSWECKI			
Attorney Docket Number		13/068-3-D3			

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JCO		GAUCHER, Et Al: "Palladium (0) Catalyzed Tandem Alkylation and SN' Cyclization of 1,4-Dichlorobut -2-ene by the N-(Diphenylmethylene) acetonitrile. A Stereoselective Synthesis of 1-Aminocyclo- propanecarboxylic Acids"; Tetrahedron Letters, vol 36, No.17, Pg. 2979-2982; 1995	
↓		FLICHE, Et Al; "Enantioselective synthesis of (1R,2S) and (1S,2S) dehydrocoronamic acids", Synthetic Communications; Vol. 24, No. 20, 1994, Pg. 2873-2876	
↓		CHEN, Et Al; "Chirally selective hydrolysis of D, L amino acid esters by alkaline protease"; J. Chem. Soc. Chem. Commun., Vol. 20, 1986, Pg. 1514-1516	
↓		CHEN, Et Al; "Kinetic resolution of esters of amino acids in t-butanol containing 5% water catalyzed by a stable industrial alkaline protease"; Chirality, Vol. 6, 1994, Pg 572-576	
↓		LLINAS-BRUNET, M., Et Al; "Peptide-based inhibitors of the hepatitis C virus serine protease", Bioorganic & Medicinal Chemistry Letters, Vol. 8, No. 13, Pg 1713-1718; 1998	
↓		GERSHONOV Et Al; "1-Aminocyclobutanecarboxylic acid derivatives as novel structural elements in bioactive peptides: application to tuftsin analogs"; Journal of Medicinal Chemistry, Vol 39, No. 24, 1996, Pg 4833-4843	
↓		OGAWA, TOMOHISA ET AL: "2,3-METHANOPHENYLALANINE AND ALPHA., .BETA.-DEHYDROPHENYLALANINE DERIVATIVES AS CHYMOTRYPSIN INHIBITOR"; PEPT. CHEM. (1990), Vol.27; Pg 379-382	

Examiner Signature J. Oswecki	Date Considered 4-12-01
--	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.